43 results about "Protamine" patented technology

The invention discloses tetrapeptide KA4 with an anti-fatigue function as well as a preparation method and application of the tetrapeptide KA4, and belongs to the technical field of biology. The tetrapeptide KA4 is screened from pacific salmon protamine enzymatic hydrolysate, the amino acid sequence is KYPA, and the tetrapeptide KA4 has strong binding capacity with KEAP1, AMPK and LDH, can significantly reduce the serum lactic acid content of a fatigue model mouse and significantly increase the load swimming time of the fatigue model mouse, has an anti-fatigue function, and can be applied to development of functional food for relieving fatigue.

The invention relates to a nanoparticle system for small intestine delivery, which is used for delivering exogenous miR-122-5p to the intestinal tract and comprises a miRNA-protamine compound inner core, a liposome middle layer wrapping the inner core and a p123 functional shell wrapping the liposome. Due to the adoption of the technical scheme, a nano-targeting delivery technology is combined with paternal epigenetic programming intervention for the first time, and a brand-new nano-drug treatment thought is provided for intergenerational genetic diseases caused by exposure of environmental adverse factors. By delivering exogenous miR-122-5p to the intestinal tract, the miRNA spectrum unbalanced due to exposure of paternal BaP can be directly improved.

The invention discloses an efficient extraction method of blue fox sperm DNA, and belongs to the technical field of molecular biology. Aiming at the structural characteristics that chromatin of the blue fox sperms is highly condensed, histone is replaced by protamine, and a stable nucleoprotein complex is formed through an intermolecular disulfide bond, the invention provides an efficient DNA extraction method suitable for the blue fox sperms. According to the method, based on the synergistic effect of three chemical reagents, namely SDS, PK and DTT, full lysis of the sperm cells of the blue foxes is achieved, and then efficient enrichment of sperm DNA of the blue foxes can be achieved by combining a conventional DNA extraction method. According to the efficient extraction method of the blue fox sperm DNA provided by the invention, the yield and integrity of the blue fox sperm DNA are remarkably improved, and the limitation that sperm chromatin is difficult to effectively lyse by a conventional method is overcome; the method provides reliable technical support for research on genetic diversity evaluation, population management, molecular breeding and the like of the blue foxes, and has the potential of popularization and application in other high-condensation sperm species.

The invention discloses a coregonus peled protamine peptide enzymolysis device and method, and belongs to the technical field of coregonus peled protamine peptide enzymolysis, and the coregonus peled protamine peptide enzymolysis method comprises the steps of pretreatment, ultrasonic-assisted acid extraction, precipitation and composite purification, and multistage impurity removal and refining. The target protein is promoted to be fully dissolved out; the coregonus peled protamine peptide enzymolysis device is composed of a supporting mechanism, a stirring mechanism, a first adjusting mechanism, a second adjusting mechanism and a switching mechanism. The supporting mechanism is matched with various stirring barrels through external threaded pipes of different specifications. The first adjusting mechanism adjusts the immersion position of the stirring blade by means of bevel gear transmission, and the deep vortex and cavitation effect are avoided; the second adjusting mechanism drives a screw rod through a gear to adjust the distance between the stirring blades and the barrel wall, and a stirring dead zone is eliminated; the switching mechanism completes vacuum degassing and nitrogen filling through a three-way switching valve, foam is inhibited, and sample oxidation is prevented.

The invention discloses a hexapeptide VA6 with an anti-fatigue function as well as a preparation method and application thereof, and belongs to the technical field of biology. The hexapeptide VA6 is screened from pacific salmon protamine enzymatic hydrolysate, the amino acid sequence is VGVVVA, the binding capacity with AMPK and LDH is high, the liver glycogen content of a fatigue model mouse can be remarkably increased, the serum urea nitrogen content of the fatigue model mouse can be remarkably reduced, the fatigue phenotype of the fatigue model mouse can be remarkably relieved, and the load swimming time of the fatigue model mouse can be remarkably prolonged; the food has an anti-fatigue function and can be applied to development of functional food for relieving fatigue.

The present invention belongs to the field of molecular biology and genetics, and in particular relates to a method for editing a bovine gene based on Pro-iCHI. The present invention provides a method for editing a bovine gene based on Pro-iCHI. Protamine is transiently expressed in gene-edited b-haSCs, which are then injected to mature oocytes to obtain reconstructed embryos. Protamine can eliminate abnormal DNA methylation resulting from oocyte intracytoplasmic haSCs injection and enable the nucli to compress into sperm-like structures, and the obtained bovine Pro-iCHI embryos can successfully develop into blastocysts, with a blastocyst rate comparable to that of the embryos obtained by in vitro fertilization. Moreover, in the present invention, a protamine-encoding gene is inserted into a Saccharomyces cerevisiae protein expression vector for transient expression, which ensures that abnormal DNA methylation is erased, without integration into the genome resulting in the insertion of exogenous genes.

The invention discloses a pentapeptide YP5 with a function of relieving diabetic kidney injury as well as a preparation method and application of the pentapeptide YP5, and belongs to the technical field of biology. The pentapeptide YP5 is screened from pacific salmon protamine enzymatic hydrolysate, the amino acid sequence is YVAAP, and the pentapeptide YP5 has the function of relieving the diabetic kidney injury, can remarkably reduce the content of fasting blood-glucose, serum creatinine, urea nitrogen and urine protein of diabetic mice, has better activity and smaller toxic and side effects than a positive drug metformin, and can be used for preparing the medicine for treating diabetic kidney injury. The method can be applied to functional food for relieving diabetic kidney injury.

The invention belongs to the technical field of biological medicine, and particularly relates to a heparin small molecule antagonist-quaternary ammonium salt macrocyclic compound and a preparation method thereof. The quaternary ammonium salt macrocyclic compound disclosed by the invention comprises three piperazine functionalized quaternary ammonium salt macrorings and four methylated quaternary ammonium salt macrorings; the quaternary ammonium salt macrocyclic compound can be used for preparing a heparin small molecule antagonist. The compound shows excellent antagonism efficiency on ungraded heparin and low-molecular-weight heparin, and shows a wide therapeutic dose window; and the antagonism efficiency and dosage window of the protamine are superior to those of clinically used protamine. Besides, in-vivo and in-vitro safety evaluation proves that the quaternary ammonium salt macrocycle has good biocompatibility, and shows clinical transformation potential as a protamine substitute as a small molecule antagonist.

The present invention relates to preparation method for the scale up production of a safe bovine heparin composed by a distinctively selected unfractioned bovine heparin polymers with low 6-O-desulfated glucosamine content and a porcine-like anticoagulant activity and protamine neutralization, and methods of its production and application. This safe bovine heparin (SB Heparin) has a comparable structure and function to the porcine heparin, the clinical usage reference, preventing clinical usage impairments as a safe pharmaceutical product, allowing its use as interchangeably drugs.

The present invention relates to a cancer-targeting drug delivery system comprising: a protamine-based self-assembling first nanoparticle including a negatively charged substance; and a heparin-based self-assembling second nanoparticle including a positively charged anticancer agent and Fe3+. Specifically, the present invention provides a drug delivery system that forms aggregates at a tumor site by a guidance effect upon administration of the second nanoparticle after administration of the first nanoparticle, and has an anticancer effect through induction of ferroptosis and immunogenic cell death without exhibiting the anticoagulant effect of heparin.

This invention relates to protamine molecules. More specifically, this invention relates to protamine molecules and their use in the delivery of payload molecules.

The invention discloses a protamine mediated fluorescence resonance energy transfer (FRET) sensing system and application thereof. According to the protamine, a tetraphenylethylene-derived anionic molecule (4, 4 '-(((1, 2-stilbene-1, 2-disubunit) bis (4, 1-phenyl)) bis (aza-disubunit)) bis (4-sodium oxobutyrate)) is electrostatically enriched on the surface of the protamine, and a tetraphenylethylene group emits fluorescence after being aggregated and acts as an energy donor; furthermore, cationic dye (4-(4-dimethylaminostyryl)-1-methyl iodide pyridine) is added as an energy receptor, and a fluorescence resonance energy transfer (FRET) system is constructed. Through construction of the FRET system, long-wavelength fluorescence emission can be obtained, high-sensitivity detection of trypsin and screening of enzyme preparations are achieved, and the FRET system is expected to be applied to complex media.

An anticoagulant heparin-chondroitin chimeric saccharide molecule as well as a preparation method and application thereof are disclosed. The anticoagulant heparin-chondroitin chimeric saccharide molecule has a structure as shown in formula I. The heparin-chondroitin chimeric saccharide molecule of the present disclosure has potent activities against an Xa factor and IIa, and the activity of the heparin-chondroitin chimeric saccharide molecule can be effectively neutralized by protamine, with a neutralization rate of greater than or equal to 70%. The risk of causing adverse reactions such as fatal HIT is obviously lower than that of enoxaparin and other low-molecular-weight heparins. The heparin-chondroitin chimeric saccharide molecule disclosed by the present disclosure is suitable for the preparation of a safer potent anticoagulant and antithrombotic new drug.

The invention relates to a hypertension implant rod and a preparation method thereof, and relates to the technical field of hypertension implant rods, the hypertension implant rod comprises a quick release layer, a slow release layer and a long-acting regulation and control layer from outside to inside, the quick release layer comprises, by mass, 60-70% of bacterial cellulose (BC), 15-25% of polydopamine (PDA), 3-8% of ciprofloxacin, 3-8% of protamine and 4-6% of indapamide, the slow release layer comprises, by mass, 20-30% of a long-acting regulation and control layer, and the long-acting regulation and control layer comprises, by mass, 20-30% of a slow release layer and 20-30% of a long-acting regulation and control layer. The sustained release layer is prepared from 55 to 65 percent of polylactic acid-glycolic acid copolymer, 20 to 30 percent of cross-linked gelatin, 8 to 12 percent of lacidipine and 4 to 6 percent of spirolactone, and the long-acting regulation and control layer is prepared from 65 to 75 percent of L-polylactic acid, 20 to 30 percent of beta-glycine crystal, 3 to 5 percent of silk fibroin (SF), 0.5 to 1.0 percent of calcitonin gene related peptide CGRP and 0.1 to 0.3 percent of neuropeptide Y. The hypertension implant rod can be matched with various treatment cycles through gradient degradation, realizes'on-demand treatment ', is high in biocompatibility, is suitable for subcutaneous implantation, and is convenient and safe to operate.

The present invention relates to a lipid nanoparticle-based drug delivery system using recombinant protamine and a method for preparing same. The lipid nanoparticle-based drug delivery system of the present invention can stably deliver a gene to a target cell in vivo by using a recombinant protamine protein having excellent stability when forming a complex with an anionic gene. In addition, the lipid nanoparticle-based drug delivery system can improve the expression level of the gene in the target cell, and thus can be effectively used in related technical fields such as lipid nanoparticle-mediated gene therapy.

The present invention discloses a fluorescent probe containing a pyrene group, and its preparation method and application. The fluorescent probe described in the present invention is a ratiometric fluorescent molecule that binds to protamine through electrostatic interaction to induce the emission of an excimer. The addition of trypsin can hydrolyze the protamine, and the fluorescence can be restored to monomer emission, thereby enabling the detection of trypsin. In addition, the probe forms a host-guest complex system with γ-cyclodextrin, exhibiting the fluorescence emission of the excimer. Based on the hydrolysis of cyclodextrin by α-amylase, the fluorescence can be restored to monomer emission, thereby enabling the quantitative detection of α-amylase. The present invention provides a multifunctional fluorescent detection probe with excellent selectivity and sensitivity, which can be used in a diluted serum environment.

The present invention relates to protamine molecules. More specifically, the present invention relates to protamine molecules and their use in delivering payload molecules.

The invention discloses a cationic fluorescent probe with long wavelength emission as well as a preparation method and application of the cationic fluorescent probe. The fluorescent probe disclosed by the invention has the characteristic of emitting red fluorescence, the probe is combined with heparin through electrostatic interaction, and the fluorescence is quenched, so that the heparin is detected; furthermore, the protamine is specifically combined with the heparin, probe molecules are released, fluorescence is recovered, and the protamine is detected; the long-wavelength fluorescent probe provided by the invention has good selectivity and sensitivity on heparin and protamine, and can be applied to a serum dilution environment.

The invention relates to the technical field of heparin and protamine analysis, in particular to a method for determining the dosage of heparin and protamine. The method comprises the steps that a first sample set A is obtained, Ai is the ith first sample, and Ai is obtained by adding different doses of preset chemical substances into a blood sample of a target individual; acquiring a whole blood activation blood coagulation time detection result set B; obtaining a target model according to the whole blood activation coagulation time detection result in the step B, the dosage of the corresponding added preset chemical substance and the preset model; and according to the target whole blood activated coagulation time and the target model, obtaining the dosage of a preset chemical substance corresponding to the target whole blood activated coagulation time of the target individual. According to the method, the heparin dosage and the protamine dosage which are suitable for the target individual and correspond to the target whole blood activation coagulation time can be determined, and reference is provided for the heparin dosage and the protamine dosage in an actual application scene.

The invention discloses a tetrapeptide FP4 with a function of relieving diabetic kidney injury as well as a preparation method and application of the tetrapeptide FP4, and belongs to the technical field of biology. The tetrapeptide FP4 is obtained by screening from pacific salmon protamine enzymatic hydrolysate, has an amino acid sequence of FGVP, has the function of relieving the diabetic kidney injury, can significantly reduce the contents of fasting blood-glucose, serum creatinine, urea nitrogen and urine protein of diabetic mice, has better activity and smaller toxic and side effects than a positive drug metformin, and can be used for preparing drugs for treating diabetic kidney injury. The method can be applied to functional food for relieving diabetic kidney injury.

The present invention discloses a tetrapeptide KA4 with anti-fatigue properties, as well as its preparation method and application, belonging to the field of biotechnology. The tetrapeptide KA4, screened from Pacific salmon sperm protease hydrolysate, has an amino acid sequence of KYPA and exhibits strong binding abilities to KEAP1, AMPK, and LDH. It can significantly reduce serum lactate levels and increase the weighted swimming time of fatigue model mice. It exhibits anti-fatigue properties and can be used in the development of functional foods that alleviate fatigue.

The present invention discloses a hexapeptide VA6 with anti-fatigue function, as well as its preparation method and application, belonging to the field of biotechnology. The hexapeptide VA6, screened from Pacific salmon sperm protein hydrolysate, has an amino acid sequence of VGVVVA and strong binding ability to AMPK and LDH. It can significantly increase the liver glycogen content and significantly reduce the serum urea nitrogen content in fatigue model mice, alleviate the fatigue phenotype of fatigue model mice, and significantly increase the weighted swimming time of fatigue model mice. It has anti-fatigue function and can be used in the development of functional foods that relieve fatigue.

The invention discloses a composition for repairing gene cells and improving cardiovascular and cerebrovascular diseases, and belongs to the technical field of natural health products. The composition comprises salmon extract, protamine powder, nucleotide type yeast hydrolysate, L-arginine, sorbitol, maltodextrin, inulin, roxburgh rose powder, gamma-aminobutyric acid, sodium bicarbonate, xylooligosaccharide, vitamin B1 and vitamin B2, and all the components are proportioned in specific parts by weight. During preparation, part of the extract is obtained through alcohol extraction or water extraction, and powder or tablets are prepared through the steps of mixing, heating and stirring, drying, grinding, pelleting and the like. Through the synergistic effect of multiple components, the traditional Chinese medicine composition not only can repair gene cells, but also can improve cardiovascular and cerebrovascular functions and optimize microcirculation, is high in safety and is suitable for people with related requirements.

A method of erasing an abnormal epigenetic modification in a sheep iCHI embryo and use thereof. A method including the steps of: transferring a recombinant plasmid expressing protamine into a sheep androgenetic haploid embryonic stem cell, then introducing the cell into a mature sheep oocyte, and performing activation and culture to obtain a sheep iCHI embryo without abnormal epigenetic modifications. In the present disclosure, abnormal methylations in iCHI embryos may be erased by transient expression of protamine in o-haSCs. The blastocyst rate of the prepared Pro-iCHI embryos is significantly higher than that of iCHI embryos, and is similar to that of IVF embryos. The resulting embryos can be used for embryo transfer to obtain semi-cloned gene-edited sheep, providing materials for subsequent breeding applications.

The present invention discloses a pentapeptide YP5 that can alleviate diabetic kidney damage, as well as its preparation method and application, belonging to the field of biotechnology. The pentapeptide YP5, obtained by screening from Pacific salmon sperm protease hydrolysate, has the amino acid sequence YVAAP and can alleviate diabetic kidney damage. It can significantly reduce fasting blood glucose, serum creatinine, urea nitrogen, and urine protein in diabetic mice. It has superior activity and fewer toxic side effects than the positive drug metformin, and can be used in functional foods that alleviate diabetic kidney damage.

The invention discloses fully sulfated chondroitin sulfate, a preparation method thereof and application of the fully sulfated chondroitin sulfate in inhibiting CRISPR / Cas, the structure of the fully sulfated chondroitin sulfate is shown as VII, the fully sulfated chondroitin sulfate polysaccharide can prevent specific binding of Cas9 and gRNA and inhibit the cleavage activity of Cas9, the Cas9 can be represented by fluorescence intensity, and the Cas9 and gRNA can be combined with gRNA. Meanwhile, the protamine can promote the fully sulfated chondroitin to enter escherichia coli to play a role. According to the invention, full sulfated chondroitin (VII) with a clear structure is found to be used as a non-protein inhibitor to inhibit the activity of CRISPR / Cas, and protamine is used as an auxiliary agent to promote the full sulfated chondroitin to rapidly achieve the inhibition effect. # imgabs0 #

This invention provides an impregnated paper with anti-mildew, antibacterial, and antiviral properties, and its preparation process. The impregnated paper comprises the following raw materials by percentage: 0.8-1.4% plant extract, 45-57% film-forming resin, 1-1.5% calcium peroxide, 1-1.5% protamine, 0.5-0.8% capsid protein, 0.3-0.5% oligosaccharide chain protein, 3-4% nano-sepiolite, 0.8-1.2% calcium hypochlorite, 0.1-0.2% silver-loaded nanoparticles, 6-8% slow-release carrier, 0.6-0.8% photoinitiator, 0.3-0.5% surfactant, 3-4% plasticizer, 0.1-0.2% curing agent, 0.2-0.3% dispersant, 0.2-0.4% crosslinking agent, 0.2-0.3% moisture-proof agent, 0.2-0.4% antioxidant, 0.1-0.3% antistatic agent, and the balance being solvent. The combined effect of the components in this invention enables the impregnated film paper to possess excellent comprehensive properties such as mildew resistance, antibacterial properties, and antiviral properties, reducing the probability of bacterial and viral transmission and improving the practicality and safety of the impregnated film paper in decorative panels for underfloor heating environments, humid areas (such as bathroom cabinets), or medical facilities.

The present invention provides a mesenchymal stem cell drug formulation and its preparation process, belonging to the field of biomedical technology. The mesenchymal stem cell drug formulation combination provided by the present invention includes a mesenchymal stem cell solution and a self-assembly solution; the mesenchymal stem cell solution is composed of mesenchymal stem cells, human serum albumin, heparin, dextran 40, and a compound electrolyte solution, and the self-assembly solution is composed of protamine, dipotassium glycyrrhizinate, rosmarinic acid, and physiological saline. The mesenchymal stem cell drug formulation combination provided by the present invention can improve the cell activity and stability of mesenchymal stem cells, highly express CD73, CD90, CD105, HGF, and sTNFR1, and has a good immune regulation function, providing a new idea for the clinical application of mesenchymal stem cells.

The invention provides a method for improving lentivirus transfection efficiency of macrophages. The method comprises the following steps: extracting CD14 < + > mononuclear cells from peripheral blood, inducing the CD14 < + > mononuclear cells to be polarized into M1 type macrophages, then inhibiting expression of SAMHD1 genes in the macrophages from a transcription or translation level, treating the macrophages which reduce the expression of the SAMHD1 genes by dNTPs, and then performing lentivirus transfection. The positive rate and the cell viability after lentivirus transfection of macrophages are effectively improved by optimizing the protamine content of a culture medium, the transfection volume and the like during lentivirus transfection of the macrophages. On the basis, siRNA is adopted to interfere SAMHD1 gene expression and is combined with dNTPs treatment, so that the lentivirus transfection positive rate of the macrophages is increased, the M1 phenotype of the macrophages is maintained, the operation is simple and effective, the cost is low, and the method is suitable for industrial large-scale production.

The application relates to the technical field of heparin and protamine analysis, in particular to a heparin and protamine dose determination method. The method comprises the following steps: obtaining a first sample set A, wherein A i is the ith first sample, A i is obtained by adding different doses of a preset chemical substance in a blood sample of a target individual; obtaining a whole blood activated coagulation time detection result set B; obtaining a target model according to the whole blood activated coagulation time detection result in B, the dose of the corresponding added preset chemical substance and a preset model; and obtaining the dose of the preset chemical substance corresponding to the target whole blood activated coagulation time of the target individual according to the target whole blood activated coagulation time and the target model. The application can determine the heparin dose and the protamine dose suitable for the target individual and corresponding to the target whole blood activated coagulation time, and provides a reference for the heparin dose and the protamine dose in an actual application scene.